J8522
J8522 – Capecitabine, oral, 50 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 27 NDCs crosswalked per 50 MG $0.080/unit ASP+6%
📋 J8522 summary
J8522 is a HCPCS Level II J-code used to bill Capecitabine, oral, 50 mg, billed per 50 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J8522: Capecitabine
Code J8522
Billing unit 50 MG Payment limit $0.080/unit NDC-Crosswalk 27
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ8522
DescriptorCapecitabine, oral, 50 mg
Billing unit50 MG
Payment limit / unit$0.080
Est. ASP / unit$0.075 est.
Mapped NDCs27
Data periodQ3 2026
Last updated2026-08-20
💊 About Capecitabine DRUG GUIDE
Capecitabine tablets are used to treat several types of cancer.
For colorectal cancer, they can be used after surgery for Stage III colon cancer, for locally advanced rectal cancer alongside radiation, or for cancer that has spread or cannot be removed surgically.
For breast cancer, capecitabine can be used alone when certain other chemotherapy types aren't appropriate, or in combination with docetaxel after prior treatment.Xeloda (capecitabine) is also approved for unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as part of a combination regimen, including for HER2-overexpressing tumors.
Xeloda is additionally approved for adjuvant treatment of pancreatic adenocarcinoma in combination with other chemotherapy agents.
Clinical overview from our editorial drug guide for Capecitabine. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.080
Est. ASP / unit
$0.075 est.
Est. after 2% sequester
$0.078
HCPCS dosage
50 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J8522 = 50 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J8522 LEAST EXPENSIVE FIRST
27 NDCs map to J8522. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.080/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00093-7473-06 | Capecitabine 150 mg/1 TABLET, FILM COATED | Teva | 60 TABLET, FILM COATED in 1 BOTTLE (0093-7... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 16729-0072-12 | CAPECITABINE 150 mg/1 TABLET, FILM COATED | Accord | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 55111-0496-60 | capecitabine 150 mg/1 TABLET | Dr. | 60 TABLET in 1 BOTTLE (55111-496-60) | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 59651-0204-60 | Capecitabine 150 mg/1 TABLET | Aurobindo | 60 TABLET in 1 BOTTLE (59651-204-60) | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 67877-0458-60 | Capecitabine 150 mg/1 TABLET, FILM COATED | Ascend | 60 TABLET, FILM COATED in 1 BOTTLE (67877-... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 68001-0487-06 | CAPECITABINE 150 mg/1 TABLET, FILM COATED | BluePoint | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 68001-0643-06 | Capecitabine 150 mg/1 TABLET, FILM COATED | BluePoint | 60 TABLET, FILM COATED in 1 BOTTLE (68001-... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 69097-0949-03 | Capecitabine 150 mg/1 TABLET, FILM COATED | Cipla | 60 TABLET, FILM COATED in 1 BOTTLE (69097-... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 70756-0815-60 | Capecitabine 150 mg/1 TABLET, FILM COATED | Lifestar | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTI... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 72205-0006-60 | Capecitabine 150 mg/1 TABLET, FILM COATED | Novadoz | 60 TABLET, FILM COATED in 1 BOTTLE (72205-... | 150 mg/1 | 180 | $14.40 | $0.362 | ● Active | CMS ASP |
| 00093-7474-89 | Capecitabine 500 mg/1 TABLET, FILM COATED | Teva | 120 TABLET, FILM COATED in 1 BOTTLE (0093-... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 16729-0073-29 | CAPECITABINE 500 mg/1 TABLET, FILM COATED | Accord | 120 TABLET, FILM COATED in 1 BOTTLE, PLAST... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 55111-0497-04 | capecitabine 500 mg/1 TABLET | Dr. | 120 TABLET in 1 BOTTLE (55111-497-04) | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 59651-0205-08 | Capecitabine 500 mg/1 TABLET | Aurobindo | 120 TABLET in 1 BOTTLE (59651-205-08) | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 60687-0149-94 | Capecitabine 500 mg/1 TABLET, FILM COATED | American | 20 BLISTER PACK in 1 BOX, UNIT-DOSE (60687... | 500 mg/1 | 200 | $16.00 | $0.468 | ● Active | CMS ASP |
| 67877-0459-12 | Capecitabine 500 mg/1 TABLET, FILM COATED | Ascend | 120 TABLET, FILM COATED in 1 BOTTLE (67877... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 68001-0644-07 | Capecitabine 500 mg/1 TABLET, FILM COATED | BluePoint | 120 TABLET, FILM COATED in 1 BOTTLE (68001... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 69097-0948-08 | Capecitabine 500 mg/1 TABLET, FILM COATED | Cipla | 120 TABLET, FILM COATED in 1 BOTTLE (69097... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 70756-0816-22 | Capecitabine 500 mg/1 TABLET, FILM COATED | Lifestar | 120 TABLET, FILM COATED in 1 BOTTLE, PLAST... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 72205-0007-92 | Capecitabine 500 mg/1 TABLET, FILM COATED | Novadoz | 120 TABLET, FILM COATED in 1 BOTTLE (72205... | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 82009-0112-12 | Capecitabine 500 mg/1 TABLET | Quallent | 120 TABLET in 1 BOTTLE (82009-112-12) | 500 mg/1 | 1,200 | $96.00 | $0.468 | ● Active | CMS ASP |
| 68001-0488-07 | CAPECITABINE 500 mg/1 TABLET, FILM COATED | BluePoint | 120 TABLET, FILM COATED in 1 BOTTLE, PLAST... | 500 mg/1 | 1,200 | $96.00 | $0.481 | ● Active | CMS ASP |
| 00004-1100-20 | Xeloda | Genentech, | — | — | 180 | $14.40 | — | — | CMS ASP |
| 00004-1101-50 | Capecitabine | Genentech, | — | — | 1,200 | $96.00 | — | — | CMS ASP |
| 16714-0467-01 | Capecitabine | Northstar | — | — | 180 | $14.40 | — | — | CMS ASP |
| 16714-0468-01 | Capecitabine | Northstar | — | — | 1,200 | $96.00 | — | — | CMS ASP |
| 61269-0470-60 | Xeloda | H2 | — | — | 180 | $14.40 | — | — | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$562.7K
Claims
21,052
Beneficiaries
9,046
Spend / beneficiary
$62.20
Spend / claim
$26.73
Trend by period
Where J8522 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #429 of 824
#424
NOVOEIGHT J7182
$581.9K
#425
NUZYRA J0121
$578.1K
#426
ACETYLCYSTEINE J7608
$575.2K
#427
MYLOTARG J9203
$570.9K
#428
GRAFIX PLUS, PER SQ... Q4304
$566.2K
#429
CAPECITABINE* J8522
$562.7K
#430
OMNIPAQUE Q9965
$559.4K
#431
PRIALT J2278
$553.3K
#432
MILRINONE IN 5% DEXT... J2260
$551.1K
#433
RAPAMUNE* J7520
$539.9K
#434
CORIFACT J7180
$532.3K
Total claims — #101 of 824
#96
LEUCOVORIN CALCIUM J0640
21,924
#97
ABRAXANE* J9264
21,913
#98
GRANISETRON HCL J1626
21,847
#99
DEXTENZA J1096
21,748
#100
POSFREA J2468
21,414
#101
CAPECITABINE* J8522
21,052
#102
NUCALA J2182
20,909
#103
DUROLANE J7318
20,869
#104
TEZSPIRE J2356
20,787
#105
NEULASTA ONPRO* J2506
20,607
#106
MONOVISC J7327
20,428
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $562.7K | 9,046 | 21,052 | $62.20 | $26.73 |
| 2025 (Q1-Q4) | $3.94M | 20,936 | 96,324 | $188.18 | $40.90 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$19.9K
Medicare paid
$14.9K
Submitted services
844,465
Denial rate
49.7%
Allowed / service
$0.05
Submitted charges
$11.45M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
27 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J8522 billing FAQ
What is HCPCS code J8522?
J8522 is a HCPCS Level II J-code used to bill Capecitabine, oral, 50 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J8522?
One unit of J8522 represents 50 MG. Report the number of units equal to the dose administered divided by 50 MG.
How many units of J8522 should I bill?
Divide the dose administered by the code's unit size (50 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J8522?
The Medicare Part B payment limit is $0.080 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.078 per unit. Payment limits are revised quarterly.
Which NDCs bill under J8522?
27 NDCs currently map to J8522 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J8522 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.